Literature DB >> 17327790

Stereotactic radiosurgery for vestibular schwannomas in patients with neurofibromatosis type 2: an analysis of tumor control, complications, and hearing preservation rates.

David Mathieu1, Douglas Kondziolka, John C Flickinger, Ajay Niranjan, Richard Williamson, Juan J Martin, L Dade Lunsford.   

Abstract

OBJECTIVE: Vestibular schwannomas present significant management challenges in patients with neurofibromatosis Type 2 (NF2). We evaluated the results of gamma knife radiosurgery for the management of these tumors, focusing on tumor response, hearing preservation, and other factors affecting outcomes.
METHODS: Stereotactic radiosurgery was performed to manage 74 schwannomas in 62 patients. Ipsilateral serviceable hearing was present in 35% of tumors before the procedure. The mean tumor volume was 5.7 cm3. The mean margin and maximum dose used were 14 and 27.5 Gy, respectively. Cox regression analyses were performed to identify factors affecting outcomes.
RESULTS: The median follow-up period was 53 months, and two patients were lost to follow-up. Actuarial local control rates at were 85, 81, and 81% at 5, 10, and 15 years, respectively. Tumor volume was significant as a predictor of local control. Since 1992, using current radiosurgery techniques (magnetic resonance imaging scan targeting and reduced margin dose to 14 Gy or less), the actuarial serviceable hearing preservation rate is 73% at 1 year, 59% at 2 years, and 48% at 5 years after radiosurgery. Facial neuropathy occurred in 8% of tumors, trigeminal neuropathy occurred in 4%, and vestibular dysfunction occurred in 4%. Radiation dose and tumor volume were predictive of development of new deficits. No radiosurgery-associated secondary tumors or atypical or malignant changes were noted.
CONCLUSION: Stereotactic radiosurgery is a safe and effective management modality for neurofibromatosis Type 2 vestibular schwannomas. Although results do not seem to be as good as for patients with sporadic unilateral tumors, gamma knife radiosurgery results seem favorable and indicate that radiosurgery should be strongly considered for primary tumor management in selected patients.

Entities:  

Mesh:

Year:  2007        PMID: 17327790     DOI: 10.1227/01.NEU.0000255340.26027.53

Source DB:  PubMed          Journal:  Neurosurgery        ISSN: 0148-396X            Impact factor:   4.654


  37 in total

1.  Consensus recommendations for current treatments and accelerating clinical trials for patients with neurofibromatosis type 2.

Authors:  Jaishri O Blakeley; D Gareth Evans; John Adler; Derald Brackmann; Ruihong Chen; Rosalie E Ferner; C Oliver Hanemann; Gordon Harris; Susan M Huson; Abraham Jacob; Michel Kalamarides; Matthias A Karajannis; Bruce R Korf; Victor-Felix Mautner; Andrea I McClatchey; Harry Miao; Scott R Plotkin; William Slattery; Anat O Stemmer-Rachamimov; D Bradley Welling; Patrick Y Wen; Brigitte Widemann; Kim Hunter-Schaedle; Marco Giovannini
Journal:  Am J Med Genet A       Date:  2011-12-02       Impact factor: 2.802

Review 2.  Neurofibromatosis type 2.

Authors:  Ashok R Asthagiri; Dilys M Parry; John A Butman; H Jeffrey Kim; Ekaterini T Tsilou; Zhengping Zhuang; Russell R Lonser
Journal:  Lancet       Date:  2009-05-22       Impact factor: 79.321

3.  Phase II study of mTORC1 inhibition by everolimus in neurofibromatosis type 2 patients with growing vestibular schwannomas.

Authors:  Stéphane Goutagny; Eric Raymond; Marina Esposito-Farese; Stéphanie Trunet; Christian Mawrin; Daniele Bernardeschi; Béatrice Larroque; Olivier Sterkers; Marco Giovannini; Michel Kalamarides
Journal:  J Neurooncol       Date:  2015-01-08       Impact factor: 4.130

4.  Risk Recall of Complications Associated with Vestibular Schwannoma Treatment.

Authors:  Khodayar Goshtasbi; Mehdi Abouzari; Omid Moshtaghi; Marlon Maducdoc; Brandon M Lehrich; Harrison W Lin; Hamid R Djalilian
Journal:  Otolaryngol Head Neck Surg       Date:  2019-03-19       Impact factor: 3.497

5.  Clinical Results After Single-fraction Radiosurgery for 1,002 Vestibular Schwannomas.

Authors:  Paul Y Windisch; Joerg-Christian Tonn; Christoph Fürweger; Berndt Wowra; Markus Kufeld; Christian Schichor; Alexander Muacevic
Journal:  Cureus       Date:  2019-12-16

6.  Options and strategies for hearing restoration in pediatric neurofibromatosis type 2.

Authors:  Hossein Mahboubi; William H Slattery; Gautam U Mehta; Gregory P Lekovic
Journal:  Childs Nerv Syst       Date:  2020-06-21       Impact factor: 1.475

7.  Malignant transformation of acoustic neuroma/vestibular schwannoma 10 years after gamma knife stereotactic radiosurgery.

Authors:  Andreas K Demetriades; Nicholas Saunders; Peter Rose; Cyril Fisher; Jeremy Rowe; Robert Tranter; Carl Hardwidge
Journal:  Skull Base       Date:  2010-09

8.  Surgical treatment of large vestibular schwannomas in patients with neurofibromatosis type 2: outcomes on facial nerve function and hearing preservation.

Authors:  Fu Zhao; Bo Wang; Zhijun Yang; Qiangyi Zhou; Peng Li; Xingchao Wang; Jing Zhang; Junting Zhang; Pinan Liu
Journal:  J Neurooncol       Date:  2018-02-28       Impact factor: 4.130

9.  Long-term natural history of neurofibromatosis Type 2-associated intracranial tumors.

Authors:  Michael S Dirks; John A Butman; H Jeffrey Kim; Tianxia Wu; Keaton Morgan; Anne P Tran; Russell R Lonser; Ashok R Asthagiri
Journal:  J Neurosurg       Date:  2012-04-13       Impact factor: 5.115

10.  Stereotactic Radiosurgery versus Natural History in Patients with Growing Vestibular Schwannomas.

Authors:  Albert Tu; Peter Gooderham; Paul Mick; Brian Westerberg; Brian Toyota; Ryojo Akagami
Journal:  J Neurol Surg B Skull Base       Date:  2015-03-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.